AZTA
Azenta, Inc.34.31
-0.77-2.19%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q1 '26
Reaffirms guidance, details fixes
Q&A reaffirmed full-year 3-5% organic growth and 300bps adjusted EBITDA expansion despite Q1 pressures, with management noting the 'job got harder' from $3-5M automated stores quality hit (remediation by Q2 end, few left of 18) and NA lab inefficiencies. They broke out 200bps gross margin lift from H2 volume (25 new NA reps ramping), ABS Kaizens (35%), pricing; 100bps OpEx. Bundling thrives within segments like gene read/write and C&I-stores; M&A funnel active, balanced vs. $250M buybacks. Academic/govt customers show green shoots. North America lags Europe. Investors watch H2 sales execution.
Key Stats
Market Cap
1.58BP/E (TTM)
64.74Basic EPS (TTM)
0.53Dividend Yield
0%Recent Filings
8-K
Azenta acquires UK Biocentre
Azenta's UK subsidiary acquired UK Biocentre on March 4, 2026, for GBP 20.5 million net of cash, plus up to GBP 1.8 million contingent on milestones. The deal positions UK Biocentre as Azenta's European hub for sample repository services, bolstering UK and continental operations. Acquisition dilutes 2026 Adjusted EBITDA margin by 35bps (pro forma) but accretes 2027-2028 growth. Integration risks loom.
10-Q
Q1 FY2026 results
Azenta's Q1 FY2026 revenue ticked up 1% y/y to $148.6M, with services surging 4% to $107.6M while products dipped 6% to $41.1M; gross margin slipped to 42.9% from 46.7% on rework costs and lower volumes. Operating loss narrowed to $7.2M from $8.7M as SG&A fell sharply, yet net loss from continuing operations improved to $5.2M ($0.11/share) versus $7.1M ($0.16/share), confirmed against 45,929k diluted shares. Cash flow from operations came in at $20.8M, with $6.2M capex yielding $14.6M FCF (derived); cash swelled to $337M, no debt. B Medical sale signed December 2025 for $63M ($9M deposited, $54M due by March 2026). Solid liquidity. Buyer financing risk looms.
8-K
Q1 revenue flat, margins slip
Azenta posted Q1 FY26 continuing ops revenue of $149M, up 1% YoY yet organic down 1%, with gross margin sliding to 42.9% from Automated Stores rework and volume dips. B Medical sale to Thelema for $63M awaits March 31 close; new $250M buyback runs to 2028. Reaffirmed FY26 organic growth of 3-5%, 300bps EBITDA margin expansion. Turnarounds zig-zag.
8-K
Director Malus resigns abruptly
8-K
Stockholders approve directors, comp
Azenta stockholders overwhelmingly elected all nine director nominees at the January 28, 2026 annual meeting, while approving executive compensation on a non-binding advisory vote and ratifying PwC as 2026 auditors. They also greenlit amending the 2020 Equity Incentive Plan, adding 2,750,000 shares. Governance locked in. Dipal Doshi and Tina S. Nova faced notable withhold votes.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
AVTR
Avantor, Inc.
11.20-0.08
BAX
Baxter International Inc.
19.05-0.48
BDX
Becton, Dickinson and Company
196.39-3.70
BLFS
BioLife Solutions, Inc.
24.61-0.04
BNGO
Bionano Genomics, Inc.
1.57+0.03
BRKR
Bruker Corporation
44.96-0.71
NOVT
Novanta Inc.
121.36+1.95
SOLV
Solventum Corporation
80.59-1.30
ZTEK
Zentek Ltd.
0.65-0.01